Elevated serum levels of immunoreactive anionic trypsin (but not cationic trypsin) signals pancreatic disease
1995; Humana Press; Volume: 18; Issue: 3 Linguagem: Inglês
10.1007/bf02784945
ISSN2363-5134
AutoresAnders Borgström, Åke Andrén‐Sandberg,
Tópico(s)Neuroendocrine Tumor Research Advances
ResumoPancreatic juice from most studied species contains two major forms of trypsin, one with anionic electrophoretic mobility and one with cationic mobility. They are referred to as anionic and cationic trypsin(ogen). The purpose of this study was to measure immunoreactive anionic trypsin (irAT) and immunoreactive cationic trypsin (irCT) in sera from patients with pancreatic cancer (n=39) and chronic pancreatitis (n=32) using two specific ELISA methods. Sera from 72 healthy persons were used as controls. Patients with pancreatic cancer showed significantly elevated serum levels of irAT median level 39 vs 20.5 μg/L in the control group (p<0.001). No differences in irCT levels were found. The ratio between irAT and irCT in serum was significantly increased (p<0.001). Patients with chronic pancreatitis showed a wide range of both irAT and irCT levels, but no significant differences compared to the control group. The ratio between irAT and irCT was, however, significantly increased also in this group of patients. The results suggest a nonparallel secretion of anionic and cationic trypsinogen in pancreatic disease. This is a pattern that has been observed in experimental forms of chronic “hyperCCKemia.”
Referência(s)